Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis

Sander Veldhuyzen van Zanten; Bruce Ritchie

doi:10.7326/J23-0121

Biomarker risk assessment model identified high-risk patients with cancer who benefit from thromboprophylaxis

Ann Intern Med. 2024 Feb;177(2):JC22. doi: 10.7326/J23-0121. Epub 2024 Feb 6.

Authors

Sander Veldhuyzen van Zanten¹, Bruce Ritchie¹

Affiliation

¹ University of Alberta, Edmonton, Alberta, Canada (S.V.V., B.R.).

PMID: 38315999
DOI: 10.7326/J23-0121

Abstract

Alexander M, Harris S, Underhill C, et al. Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP randomized clinical trial. JAMA Oncol. 2023;9:1536-1545. 37733336.

Publication types

Comment

MeSH terms

Anticoagulants / therapeutic use
Humans
Neoplasms* / complications
Neoplasms* / drug therapy
Patients
Randomized Controlled Trials as Topic
Risk Assessment
Venous Thromboembolism* / drug therapy

Substances

Anticoagulants